|
Rheumatoid Arthritis
Citations 311-320 of 841 total displayed.
|
Past content
(since Feb 2000):
|
- CLINICAL
Regression to the mean using the disease activity score in eligibility and response criteria for prescribing TNF- inhibitors in adults with rheumatoid arthritis
- M. C. Greenwood, J. Rathi, A. J. Hakim, D. L. Scott, and D. V. Doyle
Rheumatology 2007; 46: 1165-1167.
[Abstract]
[Full Text]
- CLINICAL
Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice
- S. Bombardieri, A. A. Ruiz, P. Fardellone, P. Geusens, F. McKenna, K. Unnebrink, U. Oezer, S. Kary, H. Kupper, and G. R. Burmester on behalf of the Research in Active Rheumatoid Arthritis (ReAct) Study Group
Rheumatology 2007; 46: 1191-1199.
[Abstract]
[Full Text]
- LETTERS TO THE EDITOR
Does cardiovascular risk factor profile influence prescribing of non-steroidal anti-inflammatory drugs in a rheumatoid population?
- D. J. Armstrong, A. D. Quinn, E. M. McCausland, G. D. Wright, and M. B. Finch
Rheumatology 2007; 46: 1209-1210.
[Extract]
[Full Text]
- BASIC SCIENCE
Anti-malarial agent artesunate inhibits TNF--induced production of proinflammatory cytokines via inhibition of NF- B and PI3 kinase/Akt signal pathway in human rheumatoid arthritis fibroblast-like synoviocytes
- H. Xu, Y. He, X. Yang, L. Liang, Z. Zhan, Y. Ye, X. Yang, F. Lian, and L. Sun
Rheumatology 2007; 46: 920-926.
[Abstract]
[Full Text]
- BASIC SCIENCE
MHC class II expression on myeloid cells inversely correlates with disease progression in early rheumatoid arthritis
- R. B. Mueller, A. Skapenko, J. Wendler, F. Schuch, J. R. Kalden, and H. Schulze-Koops
Rheumatology 2007; 46: 931-933.
[Abstract]
[Full Text]
- CLINICAL
Trends in economic consequences of rheumatoid arthritis over two subsequent years
- S. M. M. Verstappen, J. W. G. Jacobs, A. A. Kruize, J. C. Ehrlich, G. A. van Albada-Kuipers, H. Verkleij, E. Buskens, and J. W. J. Bijlsma
Rheumatology 2007; 46: 968-974.
[Abstract]
[Full Text]
- CLINICAL
Assessing remission in clinical practice
- M. Mierau, M. Schoels, G. Gonda, J. Fuchs, D. Aletaha, and J. S. Smolen
Rheumatology 2007; 46: 975-979.
[Abstract]
[Full Text]
- CLINICAL
Rituximab therapy in patients with resistant rheumatoid arthritis: real-life experience
- R. N. Jois, A. Masding, M. Somerville, K. Gaffney, and D. G. I. Scott
Rheumatology 2007; 46: 980-982.
[Abstract]
[Full Text]
- CLINICAL
Systemic sclerosis–rheumatoid arthritis overlap syndrome: a unique combination of features suggests a distinct genetic, serological and clinical entity
- G. Szücs, Z. Szekanecz, E. Zilahi, A. Kapitány, S. Baráth, S. Szamosi, A. Végvári, Z. Szabó, S. Szántó, L. Czirják, and C. György Kiss
Rheumatology 2007; 46: 989-993.
[Abstract]
[Full Text]
- CLINICAL
Compared clinical efficacy and bone metabolic effects of low-dose deflazacort and methyl prednisolone in male inflammatory arthropathies: a 12-month open randomized pilot study
- G. Saviola, L. Abdi. Ali, S. Shams. Eddin, A. Coppini, F. Cavalieri, L. Campostrini, S. Sacco, M. Bucci, G. Cirino, and M. Rossini
Rheumatology 2007; 46: 994-998.
[Abstract]
[Full Text]
|
|
